Table 4. Association of radiation dose and clinical factors with overall survival.
Univariable analysis was performed using Cox proportional hazards regression. HR: Hazard Ratio, CI: Confidence Interval.
| Covariate | n | HR | 95% CI | p-value |
|---|---|---|---|---|
| Dose to tumor (Gy) | 58 | 1.00 | 0.99—1.00 | 0.13 |
| Dose to normal parenchyma (Gy) | 58 | 1.00 | 0.99—1.01 | >0.9 |
| Number of extrahepatic metastatic sites | 64 | 1.17 | 0.91—1.51 | 0.2 |
| TARE device | 64 | |||
| Glass microspheres | — | — | ||
| Resin microspheres | 1.42 | 0.78—2.58 | 0.3 | |
| Extent of disease | 64 | |||
| Unilobar | — | — | ||
| Bilobar | 3.35 | 1.41—7.96 | 0.006 | |
| Number of systemic therapy lines | 64 | 1.01 | 0.95—1.08 | 0.7 |
| Hormone receptor status | ||||
| ER-positive | 64 | 0.67 | 0.35—1.30 | 0.2 |
| PR-positive | 64 | 0.96 | 0.53—1.75 | >0.9 |
| HER2-positive | 64 | 0.69 | 0.29—1.66 | 0.4 |
| Pre-TARE laboratory values | ||||
| Total bilirubin (mg/dL) | 64 | 1.17 | 0.57—2.40 | 0.7 |
| AST (units/L) | 64 | 1.02 | 1.01—1.02 | <0.001 |
| ALT (units/L) | 64 | 1.01 | 1.00—1.02 | 0.032 |
| Platelets (x10^9/L) | 64 | 1.00 | 1.00—1.01 | 0.11 |
| Percent of normal parenchyma treated | 58 | 1.00 | 0.99—1.02 | >0.9 |
| Anticoagulation | 64 | 1.18 | 0.64—2.21 | 0.6 |